Back to User profile » Dr Chih-Ming Liang
Papers published by Dr Chih-Ming Liang:
The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up
Liu AC, Tai WC, Chiu SM, Sou FM, Yang SC, Lu LS, Kuo CM, Chiu YC, Chuah SK, Liang CM, Wu CK
Infection and Drug Resistance 2023, 16:6167-6174
Published Date: 13 September 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Increased Risk of Pyogenic Liver Abscess after Endoscopic Sphincterotomy for Treatment of Choledocholithiasis
Wu CK, Hsu CN, Cho WR, Yang SC, Liu AC, Tai WC, Lee CH, Yang YH, Chuah SK, Liang CM
Infection and Drug Resistance 2021, 14:2121-2131
Published Date: 8 June 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK
Infection and Drug Resistance 2021, 14:1239-1246
Published Date: 25 March 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A Comparison Between Dexlansoprazole Modified Release–Based And Lansoprazole-Based Nonbismuth Quadruple (Concomitant) Therapy For First-Line Helicobacter pylori Eradication: A Prospective Randomized Trial [Corrigendum]
Tai WC, Liang CM, Bi KW, Kuo CM, Lu LS, Wu CK, Yang SC, Kuo YH, Lee CH, Huang CF, Hsu CN, Hsu PI, Wu DC, Hu TH, Wu KL, Chuah SK
Infection and Drug Resistance 2019, 12:3049-3050
Published Date: 25 September 2019
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/AJ1z88nc4uI/1.jpg)
Tai WC, Liang CM, Bi KW, Kuo CM, Lu LS, Wu CK, Yang SC, Kuo YH, Lee CH, Huang CF, Hsu CN, Hsu PI, Wu DC, Hu TH, Wu KL, Chuah SK
Infection and Drug Resistance 2019, 12:2923-2931
Published Date: 16 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus
Yao CC, Kuo CM, Hsu CN, Yang SC, Wu CK, Tai WC, Liang CM, Wu KL, Huang CF, Bi KW, Lee CH, Chuah SK
Infection and Drug Resistance 2019, 12:1425-1431
Published Date: 29 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial
Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK
Drug Design, Development and Therapy 2019, 13:1347-1356
Published Date: 26 April 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
Huang HT, Wang HM, Yang SC, Tai WC, Liang CM, Wu KL, Lee CH, Chuah SK
Infection and Drug Resistance 2018, 11:2073-2080
Published Date: 30 October 2018